Examkin

Question

Difficulty: MediumImmunologic and Inflammatory Processes

An attending physician is discussing the precise mechanisms of advanced immunomodulatory therapies with the medical team. Match each biological agent with its correct molecular target and primary immunopathologic mechanism of action.

  • AbataceptBinds CD80/CD86 to block T-cell costimulation
  • BelimumabInhibits B-lymphocyte stimulator (BLyS) to promote B-cell apoptosis
  • TocilizumabAntagonizes interleukin-6 (IL-6) receptors to suppress acute-phase reactant production
  • SecukinumabNeutralizes interleukin-17A (IL-17A) to reduce inflammatory cytokine release

Answer

Abatacept matches with binding CD80/CD86; Belimumab matches with inhibiting BLyS; Tocilizumab matches with antagonizing IL-6 receptors; Secukinumab matches with neutralizing IL-17A.
Each biologic agent is correctly paired with its specific mechanism of action based on its engineered molecular target. Abatacept functions as a CTLA-4 decoy for CD80/86. Belimumab binds BLyS to inhibit B-cell survival. Tocilizumab blocks the IL-6 receptor. Secukinumab neutralizes the cytokine IL-17A.

Step-by-Step Solution

1
Identify the cellular target of Abatacept.
Abatacept is a CTLA-4 analog.
CTLA-4 naturally binds CD80/86 to downregulate T-cell activation, a pathway mimicking physiologic immune checkpoint regulation.
2
Identify the cellular target of Belimumab.
Belimumab targets B-cell activating factors.
It specifically inhibits BLyS (BAFF), leading to B-cell apoptosis, which is critical in autoantibody-driven diseases like SLE.
3
Identify the cytokine pathway blocked by Tocilizumab.
Tocilizumab blocks IL-6 signaling.
It is an anti-IL-6 receptor antibody, distinguished from anti-TNF agents, and is pivotal in reducing hepatic acute-phase reactant synthesis.
4
Identify the cytokine pathway blocked by Secukinumab.
Secukinumab targets the IL-17 pathway.
It binds directly to IL-17A, disrupting the Th17 inflammatory axis often implicated in spondyloarthropathies.

Key Concept

Biological immunomodulators have highly specific molecular targets that disrupt distinct pathways in the inflammatory cascade, ranging from T-cell costimulation (Abatacept) to specific interleukins (IL-6, IL-17) and B-cell survival factors (BLyS).
Estimated Time:1m 30s
Rate this question

Topics

Immunologic and Inflammatory Processes

More questions from this topic